Background: Currently, existing regimens of genotoxic drugs have been
suggested to be complemented with molecular inhibitors as combinatorial and cocktail
approaches in malignancy.
Methods: In the last decade, attempts have been reported to test several new class of
anticancer drug such as miRNA mimetics, RNA enzymes, small molecular inhibitors,
DNA repair protein inhibitors and peptide mimetics.
Results: With the advent of rapidly growing genomic, epigenomic and proteomic data,
design and application of peptide mimetics appear to thrive and sustain for an impactful
cancer therapy. However, certain bottlenecks are envitable such as delivery of peptide
mimetics drug in clinical settings, reducing the side effects, immune responses and
Conclusion: This review discusses emerging issues and potential avenues related to the
scope and limitations of peptide mimetics in cancer treatment.